Viridian Therapeutics (VRDN) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- -$1.05
- Estimate
- -$1.03
- Surprise
- -2.3%
- Revenue (period 2026-06-30)
- $284,000
- Score today
- 5.0/10
Revenue source: xbrl.
How the report landed
Viridian Therapeutics (VRDN) reported a wider loss than forecast — adjusted EPS of -$1.05 against the -$1.03 estimate (a 2.3% shortfall).
Where TrendMatrix's rating stands now
TrendMatrix currently rates VRDN Sell at 5.0/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate; this quarter's -2.3% surprise compares with a +17.5% four-quarter average. Next scheduled report: 2026-11-05.
What argues against it
- Concentration risk — Pipeline: veligrotug
- Quality below floor (1.8 < 4.0)
- Value-trap signals (4/5): Margin compression (op margin -81.6%), High leverage (D/E 1.7), Material insider selling (4 sells, 0.06% of cap)…
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $18.38
- Price target
- $33.08
- Stop
- $17.09
- Upside to target
- +80.0%
- Reward-to-risk
- 8.8:1
Risk check: RSI 30 — a level conventionally read as oversold; trading volume is running 1.7× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-10-14 — shown for context, not personalized investment advice.
VRDN at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $2.06B
- P/E (fwd)
- -6.6
- 52-week range
- $13.18–$34.29
- Off 52-week high
- 46.4%
- RSI (14)
- 30
- Volume vs avg
- 1.70×
- Score today
- 5.0/10